Kairos Pharma Reports Zero Grade 3+ Toxicities in Lung Cancer Trial
Kairos reported interim Phase 1 data showing zero Grade 3+ toxicity with ENV-105 in osimertinib-resistant lung cancer patients. The clean safety profile strengthens the potential for a breakthrough therapy in a substantial drug resistance market.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day